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Abstract
Hypomorphic IL2RGmutations may lead to milder phenotypes than X-SCID, named variably as atypical X-SCID or X-CID.We
report an 11-year-old boy with a novel c. 172C>T;p.(Pro58Ser) mutation in IL2RG, presenting with atypical X-SCID phenotype.
We also review the growing number of hypomorphic IL2RGmutations causing atypical X-SCID.We studied the patient’s clinical
phenotype, B, T, NK, and dendritic cell phenotypes, IL2RG and CD25 cell surface expression, and IL-2 target gene expression,
STAT tyrosine phosphorylation, PBMC proliferation, and blast formation in response to IL-2 stimulation, as well as protein-
protein interactions of the mutated IL2RG by BioID proximity labeling. The patient suffered from recurrent upper and lower
respiratory tract infections, bronchiectasis, and reactive arthritis. His total lymphocyte counts have remained normal despite
skewed T and B cells subpopulations, with very low numbers of plasmacytoid dendritic cells. Surface expression of IL2RG was
reduced on his lymphocytes. This led to impaired STAT tyrosine phosphorylation in response to IL-2 and IL-21, reduced
expression of IL-2 target genes in patient CD4+ T cells, and reduced cell proliferation in response to IL-2 stimulation. BioID
proximity labeling showed aberrant interactions between mutated IL2RG and ER/Golgi proteins causing mislocalization of the
mutated IL2RG to the ER/Golgi interface. In conclusion, IL2RG p.(Pro58Ser) causes X-CID. Failure of IL2RG plasma mem-
brane targeting may lead to atypical X-SCID. We further identified another carrier of this mutation from newborn SCID
screening, lost to closer scrutiny.
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Introduction
X-linked severe combined immunodeficiency (X-SCID) ac-
counts for approximately half of all the SCID cases and has an
estimated incidence of 1:100000 male births [1]. It is caused
by mutations in interleukin-2 receptor gamma chain (IL2RG)
gene and presents with absent or profoundly diminished pe-
ripheral T and NK cells and functionally defective B cells [2,
3]. IL2RG is expressed by virtually all hematopoietic cells and
is shared by the receptors for interleukins (IL) 2, 4, 7, 9, 15,
and 21 [4]. In these receptors, it contributes to high-affinity
ligand binding and coupling with the Janus kinase 3 (JAK3)
with its cytoplasmic tail. Ligand binding induces
phosphorylation-mediated activation of receptor-associated
JAKs (1 and 3), further leading to JAK-mediated tyrosine
phosphorylation, homodimerization, and nuclear transloca-
tion of signal transducers and activators of transcription
(STATs) affecting target gene expression [5, 6].
The lack of normal IL-4, IL-7, IL-15, and IL-21 signaling
explains the classical T−B+NK− phenotype in X-SCID. IL-7
and IL-15 are required for Tand NK cell development, respec-
tively, and disturbed IL-4 and IL-21 signaling causes the in-
trinsic B cell defect [6–8]. IL-7 has a non-redundant role in T
cell development; defective IL-7-induced signaling is the
main reason for the T cell lymphopenia in X-SCID [9]. As a
result, individuals with X-SCID lack adequate T cell function
for survival [6, 10]. They present with early-onset respiratory
tract infections, diarrhea, and failure to thrive. Without stem
cell transplant or gene therapy, they usually die within the first
year of life [2, 5].
Several cases with rare hemizygous IL2RG mutations and
milder phenotypes, like X-linked combined immunodeficien-
cy (CID) or common variable immunodeficiency (CVID),
have been reported [2, 10–13]. Caused by hypomorphic mu-
tations, genetic reversions in the early progenitor cells, or ma-
ternal T or NK cell engraftment, these atypical or “leaky”
phenotypes may display preserved and/or partially functional
T and NK cell subsets [3, 10, 12, 14–19]. Typical and atypical
X-SCID have overlapping clinical features such as recurrent
bacterial and viral infections, often caused by opportunistic
pathogens. However, as the atypical X-SCID patients have
greater amounts of residual T cell function, their clinical pre-
sentation is less severe and the onset usually later when com-
pared to the classical X-SCID [10].
We report a boy with a novel c.172C>T;p.(Pro58Ser) mu-
tation in IL2RG, with impaired expression on IL-2 receptor
complex, and another boy with the same mutation caught in
newborn SCID screening. Our index patient presented with an
X-CID phenotype with normal numbers of T, B, and NK cells,
he suffered from recurrent respiratory tract infections, bron-
chiectasis, and reactive arthritis.
Methods
Genetic Analyses
DNA samples were extracted from peripheral blood and lym-
phocyte subpopulations sorted using standard methods.
Whole-exome sequencing (WES) was performed on HiSeq
1500 Rapid run (Illumina) using a SureSelect Clinical
Research Capture Exome kit (Agilent). The sequencing and
data analysis were performed as previously described [20, 21].
Validation of the candidate disease-causing variant and
screening of familial mutations in the available family mem-
bers (Fig. 1a) were conducted using PCR amplification of
genomic DNA and capillary electrophoresis using the ABI-
3730XL DNA Analyzer and BigDye Terminator Cycle
Sequencing kit (Applied Biosystems). Lymphocyte subpopu-
lation screening for the variant was performed using PCR
amplification of the genomic DNA and capillary electropho-
resis using the cycle sequencing technology (dideoxy chain
termination/cycle sequencing) on ABI-3730XL DNA
Analyzer. Detailed processing and analysis of WES along
with details for the second patient are described in the
Online Resource Supplementary text.
Cell isolation, surface staining, and basic
immunological workup
Cell isolation is described in the Online Resource
Supplementary text. Peripheral blood mononuclear cells
(PBMCs) were stained with fluorescently conjugated anti-
human CD4 , CD19 (B ioLegend ) , CD3 , CD14
(ImmunoTools), CD16, CD56 (BD Pharmigen), and CD8
(Miltenyi Biotech) antibodies for 30 min on ice. After surface
staining, SYTOX Green Dead Cell Stain (Invitrogen) was
added to the cells, and CD4+ and CD8+ T cells, CD19+ B
cells, and CD16+CD56+NK cells were sorted with BDInflux.
Basic immunological workup was performed in an accredited
laboratory. Whole-blood NK cell phenotyping and TCRVβ
repertoire sequencing are described in the Online Resource
Supplementary text.
Expression of IL2RG (CD132) and IL2RA (CD25) was
determined from CD4+ Tcells using fluorescently conjugated
anti-human CD4, CD8, CD25, CD56 (BD Biosciences), and
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CD132 (eBioscience) antibodies. Briefly, antibodies were
added directly to an aliquot of 100 μl of freshly drawn whole
blood, pre-cooled to + 4 °C. After 15-min incubation, red
blood cells were lysed (BD FACS Lysing Solution) and cells
were analyzed by flow cytometry (NovoCyte model 3000 and
NovoExpress, Acea).
STAT Phosphorylation in Response to Exogenous IL-2
and IL-21
STAT5 and STAT3 phosphorylation were measured from iso-
lated PBMCs after a 15-min stimulation in the presence of
exogenous IL-2 (10 U/ml and 320 U/ml) or IL-21 (10 ng/ml),
respectively, in pre-warmed RPMI 1640. IL-2-stimulated cells
were then fixed and permeabilized according to manufac-
turer’s protocol (Becton Dickinson) and stained with
fluorescent-conjugated CD3 (Invitrogen), CD4, CD25,
CD56 (BD Biosciences), and pSTAT5 (eBioscience) antibod-
ies. Cells were analyzed by flow cytometry (NovoCyte model
3000 and NovoExpress software, Acea). IL-21 stimulated
cells were stained with antibodies for CD4, CD8, and CD19
(BioLegend) for 20 min on ice and fixed with 4% formalde-
hyde (Thermo) for 10 min. After washing, cells were
incubated in 90% methanol at − 20 °C overnight and stained
with fluorescent conjugated anti-CD3 (BD), anti-pSTAT3
(Y705, BD), and anti-STAT3 (BD). Cells were analyzed using
BD Fortessa flow cytometer and FloJo (v10.6) software.
Quantitative PCR
CD4+ cells were purified from PBMCs by negative selection
with the human CD4+ isolation kit (Miltenyi Biotec) accord-
ing to the manufacturer’s instructions. Cells were incubated in
RPMI 1640 medium (Gibco, Thermo Fischer Scientific) sup-
plemented with 0.5% FBS (HyClone), 2 mML-glutamine and
0.1 mg/ml penicillin-streptomycin (Gibco, Thermo Fischer
Scientific); 106 cells/well at + 37 °C for 2 h prior to IL-2
stimulation (100 U/ml, Sigma). After 4-h stimulation, cells
were pelleted and snap-frozen to be further processed. Both
stimulated and unstimulated conditions were performed in
triplicates for each sample. RNAwas extracted using Qiagen
RNeasy Mini kit according to the manufacturer’s instructions.
A total of 240 ng of RNAwas used as a template for cDNA
synthesis (Bio-Rad iScript cDNA synthesis kit according to
the manufacturer’s instructions). Quantitative PCR (qPCR) in
technical triplicates was performed using Taqman protocol
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Fig. 1 Patient family pedigree, high-resolution lung computed
tomography and domain structure of IL2RG. a Family pedigree
(aWhole exome sequencing; bTargeted screening by Sanger
sequencing). b High-resolution lung computed tomography at age
6 years demonstrated centrally located bronchiectasis in both lower
lobes (thin arrows), a cluster of cystic bronchiectasis in the completely
collapsed right middle lobe (thick arrow), a fibrotic strand with small
caliper traction bronchiectasis in the left lingula (arrowhead). c
Schematic representation of the IL2RG Pro58Ser and previously
reported hypomorphic IL2RG mutations denoted (in blue). Signal
peptide (SP: positions 1-22) and domains extracellular (EC: 23-262),
fibronectin type III (FN-III): (1): 59-151; (2):154-2462, transmembrane
(TM: 263-283) and cytoplasmic: (284-369) (based on NCBI Reference
Sequence: NP_000197.1 and UniProtKB- P31785). d Structure ofHomo
sapiens IL-2 cytokine receptor complex (Protein Data Bank accession
number 2b5i). Complex contains 4 protein chains; IL-2 (magenta),
IL2RG (cyan), and IL2RA and IL2RB (both gray). The Pro58 residue
in IL2RG highlighted in red and Ser58 mutation in orange
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and probes according to the manufacturer’s instructions and
analyzed with BioRad CFX Touch Real-Time system. The
used Taqman probes are listed in the Online Resource
Supplementary text. Results were analyzed with GraphPad
Prism 7.03 software.
Blast Formation and Lymphocyte Proliferation
in Response to Exogenous IL-2
Blast formation was studied by flow-cytometric assay for spe-
cific cell-mediated immune-responses in activated whole
blood (FASCIA). Heparinized blood was diluted in RPMI
medium containing Glutamax I, gentamicin, and β-
mercaptoethanol and stimulated with IL-2 (R&D Systems)
in concentrations of 40 U/ml and 320 U/ml for 5 days. After
stimulation, cells were stained with Multitest 6-Color TBNK
reagent (BD) including CD3, CD45, CD4, CD8, CD19, and
CD16/CD56 antibodies. After red blood cells were lysed with
FACS lysing solution (BD), lymphocyte subpopulations were
analyzed for the percentage of blasts based on their light scat-
ter characteristics using flow cytometry (NovoCyte; Acea). In
studying lymphocyte proliferation, purified PBMCs were in-
cubated in culture medium (2 × 105 cells per well) in 96-well
polystyrene plates in the presence of increasing concentrations
of IL-2 (R&D Systems) for 72 h. For the last 6 h, 1 μCi of 3H-
Thymidine was added to each well. All conditions were per-
formed in triplicates. Cells were harvested using a cell har-
vester (Tomtec) and thymidine incorporation was measured
with beta-scintillation counter (MicroBeta; Perkin Elmer).
IL2RG Expressing Flp-In 293T-REx Cell Lines
Pro58Ser-mutant plasmid was created using Quick-Change
Site-Directed Mutagenesis kit (Agilent Technologies) to
wild-type IL2RG obtained from the human ORFeome collec-
tion. Constructs were further subcloned into C-terminal
MAC-tag gateway destination vector [22]. The Flp-In 293T-
REx cells (Invitrogen) were cultured as instructed by the man-
ufacturer. The constructs were transfected into cells with
FuGENE HD Transfection Reagent (Promega) together with
pOG44 Flp recombinase expression vector (Thermo Fisher
Scientific). The cells were grown under selection with
hygromycin B to create a stable cell line.
Affinity Purification and Mass Spectrometry
Affinity purification of BioID and liquid chromatography-
mass spectrometry (LC-MS), analyses were performed as pre-
viously described [22]. In BioID-method, a modified biotin
ligase is fused to the protein of interest, which enables the
biotinylation of the proteins that are proximal. The biotinylat-
ed closely interacting proteins are then affinity-purified and
analyzed with quantitative mass spectrometry [23]. Briefly,
for each pull-down, approximately 5 × 107 cells (5 × 15 cm
dishes) in two biological replicates were induced with
2 μg/ml tetracycline and 50 μM biotin (Sigma) for 24 h.
Cells were harvested, pelleted, and lysed in HENN-lysis buff-
er (HENN; 50 mM HEPES pH 8.0, 5 mM EDTA, 150 mM
NaCl, 50 mM NaF, supplemented with 0.5% NP40, 1 mM
DTT, 1.5 mM Na3VO4, 1 mM PMSF, and 1x protease inhib-
itors cocktail; Sigma). Affinity purification was done using
Strep-Tactin beads (IBA GmbH). Bound proteins were eluted
with freshly prepared D-biotin (Thermo Fisher Scientific).
The sample proteins were reduced with TCEP (Tris(2-
carboxyethyl)phosphine), alkylated with iodoacetamide, and
digested with trypsin (Promega).
LC-MS analysis was done with a Q Exactive ESI-
quadrupole-orbitrap mass spectrometer coupled to an EASY-
nLC 1000 nanoflow LC (Thermo Fisher Scientific) using the
Xcalibur version 3.1.66.10 (Thermo Fisher Scientific). For
each sample, two technical replicates were analyzed.
Database Analysis
SEQUEST search algorithm in Proteome Discoverer software
(Thermo Fisher Scientific) was used for peak extraction and
protein identification with the human reference proteome of
UniProtKB database (www.uniprot.org, Uniprot human 10_
2016, with 20,118 sequences). Allowed error tolerances were
15 ppm and 0.05 Da for the precursor and fragment ions,
respectively. Database searches were limited to fully tryptic
peptides allowing two missed cleavage and carbamidomethyl
+57,021 Da (C) of cysteine residue was set as fixed, and
oxidation of methionine +15,995 Da (M) as dynamic modifi-
cation. For peptide identification, false discovery rate was set
to < 0.05. The high-confidence protein-protein interactions
were identified using stringent filtering against green fluores-
cent protein control samples. The bait normalized relative pro-
tein abundances (% to the IL2RG) were calculated from the
spectral counts. Statistical difference was calculated with
Student’s t test. Gene ontology (GO) annotations were obtain-
ed from DAVID bioinformatics resources [24, 25].
Results
Case Report
An 11-year-old boy with normal (-1SD) growth was born to
nonconsanguineous Finnish parents (Fig.1a). At age two, he
started having recurrent upper and lower respiratory tract in-
fections, prolonged cough, and bilateral purulent middle ear
infections. At age six, tympanostomy was performed.
However, recurrent middle ear infection and purulent dis-
charge from tympanostomy tubes continued and bronchiecta-
sis was noted (Fig.1b), with cystic fibrosis and ciliary
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dyskinesia ruled out. After two bouts of post-infectious syno-
vitis in the knee at ages eight and nine, HLA-B27, rheumatoid
factor, cyclic citrullinated peptide antibodies, and antinuclear
antibodies were tested negative.
The patient’s T, B, and NK cell counts were within the
normal range, with elevated γδ lymphocyte counts compris-
ing 35.9% of CD3+ T cells. Both CD4+ and CD8+ effector
memory (TEM) populations were decreased, with almost ab-
sent CD4+ terminally differentiated effector cells (TEMRAs).
Regulatory T cell (Treg) numbers were normal. Numbers of
circulating CD27+ B memory and switched memory B cells
were very low. Plasmacytoid dendritic cells (DCs) comprised
only 0.02% of the total leukocytes (Table S1, Online
Resource). NK cell phenotyping showed that patient had in-
creased amount of CD3-CD56bright NK cells when compared
to healthy controls. Furthermore, these cells expressed highly
CD27 and inhibitory receptor NKG2A, while CD57 expres-
sion was lower than in controls (Table S2, Online Resource).
TCRVβ repertoire was comparable to healthy controls
(Table S3, Online Resource).
The patient mounted normal antibody responses to tetanus
and pneumococcal vaccines, antibodies against Haemophilus
influenzae and diphtheria reached protective levels only after
additional booster doses. Proliferative responses to mitogens
(concanavalin A, phytohemagglutinin, pokeweed) have fluc-
tuated (Table S1, Online Resource).
Patient’s plasma immunoglobulin levels have remained
normal. Due to recurrent infections and bronchiectasis,
azithromycin prophylaxis, and inhalations with hypertonic
saline, fluticasone and salbutamol were started at age sev-
en. As recurrent infections continued, intravenous immu-
noglobulin (IVIG) treatment was started at age nine. The
frequency of infections reduced without evident progres-
sion of bronchiectasis or his clinical condition. For more
detailed case report, see Supplementary text, Online
Resource.
Genetic Analysis
WES identified a novel c.172C>T hemizygous missense variant
in the IL2RG gene (ENSG00000147168:ENST00000374202:
c. 172C>T;p.(Pro58Ser)). Proline-58 is conserved and located
in the extracellular part of the IL2RG, close to the fibronectin-III
domain (Fig. 1c, d). The screening of the patient’s mother im-
plicated a de novo mutation (Fig. 1a and S1, Online Resource).
Analysis of the WES data did not reveal any other compelling
pathogenic or likely pathogenic variants in genes that could
contribute to the phenotype based on current knowledge
(Tables S4 and S5, Online Resource). Sequencing of the pa-
tient’s different lymphocyte subsets (CD4+, CD8+, CD19+)
and CD16+CD56+ NK cells confirmed the presence of the mu-
tation in all these (Fig.S1, Online Resource).
Reduced IL2RG Expression on Cell Surface Affects IL-2,
IL-15, and IL-21-Mediated Signal Transduction
In order to study if the Pro58Ser amino acid substitution in
IL2RG affects IL-2R expression on patient lymphocytes, we
stained patient’s and healthy donors’ lymphocytes with anti-
bodies specific for IL2RG (CD132) and IL2RA (CD25) and
analyzed their surface expression by flow cytometry. In the
patient, we found a clear reduction in both IL2RG and IL2RA
surface expressions on CD4+ T cells when compared to
healthy donors (Fig. 2a, b). Furthermore, we observed similar
trends of lower IL2RG surface expression in patient’s CD8+ T
and CD56+ NK cells (Table S6, Online Resource). In order to
study whether the reduced surface expression was due to low-
er IL2RG gene in expression in patient cells, we performed
qPCR on CD4+ T cells. The expression of IL2RG mRNA in
the patient’s CD4+ Tcells was at an equal or slightly increased
level compared to our healthy controls (Fig.S2, Online
Resource), indicating that Pro58Ser mutation may affect pro-
tein stability or targeting to cell surface.
To study whether signaling through IL-2R was impaired
due to themutated IL2RG, we studied STAT5 phosphorylation
in response to IL-2. At low IL-2 concentrations (10 U/ml),
STAT5 phosphorylation was evident on 5.6% of patient
CD4+ T cells compared with 11.9% and 11.6% (mean
11.8%) of CD4+ T cells in the controls (Fig. 2c). To assess if
higher IL-2 concentration can compensate the signaling de-
fect, we simulated patient and healthy control cells with
320 U/ml of IL-2, which induced STAT5 phosphorylation in
53.1% of CD4+ T cells in the study subject, compared to
STAT5 phosphorylation in 80.7% and 81.4% (mean 70.3%)
of CD4+ T cells in healthy controls (Fig. 2d). Data indicate
that the remaining IL-2R on the patient’s CD4+ T cell surface
was insufficient to mediate proper IL-2-induced STAT5
phosphorylation.
Next, we studied if reduced STAT5 phosphorylation affect-
ed the expression of known IL-2 target genes. After a 4-h
stimulation with 100 U/ml IL-2, expression of CD25 was
significantly lower in the patient cells compared to healthy
donors (approximately 4.5-fold induction in the patient vs.
8-fold induction in controls when compared to unstimulated
conditions) (Fig. 2e). In response to IL-2 stimulation, leuke-
mia inhibitory factor expression stayed at basal level in patient
cells but increased significantly in controls (Fig. 2f).
With FASCIA, lymphocyte blast formation in response to
varying IL-2 concentrations (40 U/ml and 320 U/ml) was
clearly impaired in index patient’s T (Fig. 2g, h) and NK
(Fig. 2i) cells compared to healthy controls. His PBMCs also
showed very weak proliferation responses to low concentra-
tions of IL-2 (3 to 13% of the level in healthy controls at 10 U/
ml) (Fig. 2j). At higher IL-2 concentrations (up to 320 U/ml),
an increasing proliferation response was detected in his cells
(Fig. 2j) but remained lower than in controls (21 to 58% of the
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level in healthy controls at 320 U/ml of IL-2). With
hypomorphic mutations of IL2RG, higher IL-2 concentrations
could theoretically enhance signaling through IL-2R.
However, compared to controls, high IL-2 concentrations
had no relative effect on the STAT5 phosphorylation or pro-
liferation. These data indicate that signaling through IL-2 re-
ceptor was impaired in patient lymphocytes.
Since IL2RG is also a component of IL4, IL-15, and IL-21
receptors, signal transduction for these cytokines was also
studied [4]. We found that STAT3 phosphorylation in patient’s
B cells was clearly reduced in response to 10 ng/ml of IL-21
stimulation, compared to healthy controls (Fig. 2k). However,
in T cells, we observed insignificant differences in STAT3
phosphorylation between the patient and controls (data not
shown). An significant trend towards lower STAT6 phosphor-
ylation in response to IL-4 stimulation in patient CD4+ Tcells
was noted, but it was normal in CD8+ T and CD19+ B cells
(data not shown). STAT5 phosphorylation in response to IL-
15 was normal in patient’s lymphocytes (data not shown). In
studying IL-15 responses by FASCIA, NK cells behaved nor-
mally, whereas blasting of CD4+ and CD8+ T cells was re-
duced (Fig. S3, Online Resource).
Pro58Ser-Mutation Disturbs IL2RG Plasma Membrane
Targeting
To characterize why the Pro58Ser mutation affects the cell
surface expression of IL2RG, we analyzed the interaction pro-
files of wild-type (WT) IL2RG and Pro58Ser IL2RG in
inducibly expressing HEK293 cell lines using BioID proxim-
ity labeling [22]. BioID-analysis showed 69 significantly
(p < 0.05) altered protein-protein interactions between
Pro58Ser-mutant and WT IL2RG (Table S7, Online
Resource). Localization-based classification of these altered
interacting proteins revealed a marked change in IL2RG lo-
calization; mutant IL2RG had increased interactions with ER/
Golgi and nuclear proteins, whereas interactions with the pro-
teins localized in focal adhesion were clearly diminished
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Fig. 2 IL-2 and IL-21 responses are disturbed in patient lymphocytes.
Expression of a IL2RG (CD132) and b IL2RA (CD25) on patient’s
CD4+ T cells, and phosphorylation of STAT5 in CD4+ T cells in
response to IL-2 stimulation at c low (10 U/ml) and d high (320 U/ml)
concentration. Representative histograms for the patient (left) and two
control subjects (middle, right) are shown in green as an overlay
together with FMO staining (blue). e CD25 and f leukemia inhibitory
factor (LIF) mRNA expression after 4-h stimulation with IL-2 (100 IU/
ml) determined by quantitative PCR. Represented as fold change (patient
unstimulated condition normalized as 1). g CD4+ T cell, h CD8+ T cell,
and i CD56+ NK cell blast formation in response to 40 U/ml and 320 U/
ml of IL-2 by FASCIA. j In vitro lymphocyte proliferation in response to
various concentrations of IL-2. PBMC were stimulated for 72 h with 6
different concentrations of recombinant IL-2 in a 3H-Thymidine
incorporation assay. Curves represent proliferation (in cpm) of patient’s
cells (solid line) and of three healthy controls (dotted lines) all tested in
parallel. k Phosphorylation of STAT3 in CD3-CD19+ B cells in response
to IL-21 (10 ng/ml) shown in green as an overlay with unstimulated cells
(blue). Data are representative out of three independent experiments in a–
d, and out of two in the rest. * = p < 0.05; ** = p < 0.01, determined by
unpaired t test with Welch’s correction in e–f
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(Fig. 3a). In addition, a GO analysis for their biological pro-
cesses showed that mutation significantly increased interac-
tions with proteins involved in many ER-Golgi-associated
functions, such as ER to Golgi vesicle-mediated transport
and COPII vesicle coating (Fig. 3b). These results suggest
abnormal maturation of mutant IL2RG, which causes the fail-
ure of the plasma membrane targeting and the mislocalization
of mutant IL2RG to the ER-Golgi interface.
Discussion
We report a novel IL2RG p.(Pro58Ser) mutation causing X-
CID and provide evidence for the impaired IL-2 responses
seen in the patient being caused by increased retention of the
mutated protein in ER and Golgi. Our patient’s CD4+ cells,
compared to healthy controls, showed reduced surface expres-
sion of IL2RG and IL2RA (CD25), leading to impaired STAT
phosphorylation responses to IL-2 and IL-21 (Fig. 2).
Reduced or absent cell surface expression of IL2RG, caused
by defect in the transcriptional level or by protein instability,
has been reported in hypomorphic IL2RG mutations [13,
26–30]. Direct effect of IL2RG mutation on CD25 surface
expression has been previously demonstrated in EBV-
transformed cell lines [31] and CD34+ hematopoietic progen-
itor cells [32] of X-SCID patients along with one additional
case termed as atypical X-SCID in which both absolute CD3+
counts and mitogen responses fluctuated so that unambiguous
categorization was rendered impossible [33]. The altered ami-
no acid residue resides in the extracellular domain of IL2RG
(Fig. 1c, d); theoretically, this could also affect its ligand-
binding affinity, but this remains to be studied.
During the revision process of this article, another boy
detected by newborn screening for SCID with identical muta-
tion came to our attention. He had low but not undetectable
amounts of TRECs and presented with moderately decreased
CD4+ and normal B, CD8+ and NK cell counts (Table S8,
Online Resource). He is currently 3 years old without signs of
illness. A patient with late-onset CID and probable revertant
somatic mosaicism with a different mutation in the same
Fig. 3 Pro58Ser IL2RG mutant
displays increased interactions
with ER/Golgi and nuclear
proteins. BioID analysis of
Pro58Ser mutant- and WT
IL2RG. a Interacting proteins
with a significant differences
(p < 0.05) between Pro58Ser-
mutant and WT IL2RG. The
mean fold changes are calculated
as label-free MS/MS abundances
of Pro58Ser/WT IL2RG. The
interactors are classified based on
cellular localization. Red dashed
line indicates more than two times
change on the interacting protein
abundance in Pro58Ser mutant
compared with the wild type. FA
= focal adhesion; star = no
detected in WT IL2RG (on/off-
differences). b Interacting
proteins that differ between
Pro58Ser and WTwere
categorized according to their
involvement in biological
processes (Gene Oncology,
Biological Processes terms) via
DAVID bioinformatics resources
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position (c. 172C>A, p.(Pro58Thr)) has also been reported
[12]. This patient had decreased IgA and IgG levels, occasion-
al swelling of the knee and elbow joints, recurrent interstitial
pneumonia, and watery diarrhea. He died of graft failure after
an unsuccessful hematopoietic stem cell transplantation
(HSCT).
The high-affinity heterotrimeric IL-2R receptor consists of
IL2RA (CD25), IL2RB (CD122), and IL2RG (CD132) [34].
Reduced expression of any of the receptor components may
affect IL-2 signaling [35–37]. IL2RG participates in signaling
of interleukins 2, 4, 7, 9, 15, and 21 [4–7]. Impact of IL2RG
mutations on various IL2RG-dependent pathways varies; hier-
archies in the cytokine signaling impairment have been shown
with some IL2RG-dependent signaling pathways more or less
impaired than others [26, 29, 38, 39]. In our patient, IL-2 and
IL-15 signaling in T and IL-21 signaling in B cells were im-
paired, while IL-4 signaling was insignificantly affected (Fig.
2c–k and Fig. S3b-c, Online Resource). Like in the boy caught
by SCID screening, hypomorphic IL2RGmutations frequently
present with preserved or mildly decreased TandNK cells [27,
39–41]. The moderate functional defects and normal numbers
of T, B, and NK cells in the patient also suggest partly retained
signaling (Table S1). IL-2 is required for the sustained expan-
sion of T cell populations and promotes the proliferation and
survival of T cell receptor (TCR)-activated T cells [6]. It influ-
ences effector Tcell differentiation and promotes fate decisions
in antigen receptor-activated T cells [34]. Reflecting disturbed
IL-2 signaling, our patients displayed reduced cell proliferation
in response to IL-2 and low numbers of CD4+ TEMs and
TEMRAs together with low CD8+ TEMs and T central mem-
ory cells (Fig. 2j, Tables S1, 8, Online Resource). IL-2 is also
critical for the development of Tregs in the thymus and for their
maintenance and function in the periphery; index patient’s nor-
mal numbers of Tregs and the lacking severe autoimmunity
further confirmed hypomorphism (Table S1).
IL-21 and IL-4 are produced and secreted by T follicular
helper cells (TFH) [8, 42]. IL-21 supports the differentiation
and survival of B cells and is required for germinal center
reactions, production of plasma cells and IgG class switch
recombination [43, 44]. IL-4, in autocrine fashion, enables
TFHs to activate the activation-induced cytidine deaminase
enzyme in B cells, which in turn is necessary for class-
switch recombination and affinity maturation [8]. Thus, IL-4
and IL-21 in combination are required for normal B cell func-
tion and humoral responses. Besides IL-4 and IL-21, plasma
cell differentiation also requires IL-2 [45, 46]. Our patient had
high numbers of naïve B cells but low numbers of switched
memory B cells, B memory cells, and plasmablasts, likely
caused by defective IL2RG plasma membrane targeting and
consequently impaired collaborative IL-2 and IL-21 signaling.
The patient benefited from IVIG therapy despite apparently
normal serum immunoglobulin levels. This may indicate that
his endogenous immunoglobulins may not mature into full
avidity and/or his B cell memory may not be long-lasting.
The pa t i en t a l so had ve ry low numbe r o f
plasmacytoid DCs, which could be associated with the
defective IL2RG-dependent cytokine signaling; IL-4 and
IL-15 are known survival factors for DCs [6]. Although
the IL2RG expression was reduced on the surface of
patient’s NK cells, their level in peripheral blood has
remained normal (Tables S1 and S6) [4, 34]. However,
their IL-2-stimulated blast formation was impaired (Fig.
2i), indicating that IL-2 signaling in patient’s NK cells
was partly affected by IL2RG Pro58Ser mutation.
Patient had increased proportion of CD56bright NK cells,
usually considered cytokine expressing immature cells
able to become cytotoxic upon appropriate activation
(Table S2, Online Resource) [47]. These cells expressed
highly the effector marker CD27 (84.1% of CD56bright
cells) and the inhibitory receptor NKG2A (71.5% of
CD56bright cells) and decreased amounts of CD57, a
marker for terminally matured NK cells [48, 49]. In
conclusion, patient’s CD56bright NK cells displayed char-
acteristics of both early and later NK cell development
stages. Similarly, increased frequencies of CD56bright
NK cells have been reported in a patient with CD25
deficiency [50]. Like for the case with CD25 deficiency,
our preliminary data suggest that the degranulation abil-
ity of both CD56briht and CD56dim cells was restored
when patient cells were stimulated with K562 cells
in vitro (data not shown).
In increasing numbers of genetic immunodeficiencies, in-
cluding hypomorphic SCID gene mutations, lymphocyte
numbers remain normal despite clear functional defects [51].
Numbers of reported patients carrying such mutations have
increased sharply with the increasing use of next-generation
sequencing (NGS) early in the diagnostic process. The early
use of NGS followed by functional testing of novel mutations
enables expansion of the initially described, typically very
severe phenotypes, and thus greatly facilitates the diagnosis
and targeted treatment of CID patients. In Table 1, we briefly
review the reported, putatively hypomorphic IL2RG muta-
tions [11, 13, 26–29, 38–41, 52–55]. Atypical X-SCID cases
are frequently also caused by genetic reversion [15–17, 19,
58], which can easily be detected by sequencing of different
lymphocyte subpopulations. To exclude maternal engraft-
ment, one may use HLA typing or short tandem repeat
(STR) analysis [18, 59, 60]. Frequently in historical reports,
somatic mosaicism and/or maternal T or NK cell engraftment
have not been excluded systematically or the numbers of
CD4+ and CD8+ subsets were provided without information
of the overall T cell numbers or the numbers of γδ T cells [11,
26, 38, 39, 53, 55]. In these cases, we considered the muta-
tions as potentially hypomorphic and included them in our
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review. Of note, reactive expansion of the γδ T cells seems
particularly common in atypical X-SCID patients [61].
Awell-known example of hypomorphism in IL2RG is the c.
664C>T;p.(Arg222Cys) mutation, so far reported in 18 patients
[26, 27, 38, 40, 54]. In different reports, these patients were
classified as typical or atypical, with the majority presenting with
opportunistic infections or an Omenn-like clinical presentation;
vast majority of them were treated with HSCT. Ten cases of
Arg222Cys patients were included in Table 1 and eight excluded
due to an X-SCID phenotype.
Altogether, 29 patients with atypical, putatively
hypomorphic IL2RG mutations causing atypical X-SCID
(variably named as X-CID) have been reported, including ours.
Prevalence of the most common clinical features is presented in
Fig. S4 (Online Resource). The most common feature (97%) is
susceptibility to infections, severest forms of viral and fungal
infections were rare. However, 13 (45%) patients had suffered
from infections caused by opportunistic pathogens, four despite
normal CD3+ T cell counts [27, 40]. Reported inflammatory
conditions were surprisingly rare in reviewed patients carrying
hypomorphic IL2RGmutations, with only three patients suffer-
ing from eczema or other skin rashes [11, 26, 38], two from
inflammatory arthritis [39], two from interstitial lung disease
[38], and one from inflammatory bowel disease [29].
Including our patients, 12 (41%) patients presentedwith normal
plasma/serum immunoglobulin levels (IgG normal in all; IgM,
IgA and IgE variable). Interestingly, eight (28%) of the reviewed
cases showed similarly skewed B cell subpopulations with in-
creased numbers of naïve cells and/or decreased switchedmemory
cells and plasmablasts as our index patient [26, 29, 38, 39].Despite
constantly normal immunoglobulin levels, our index patient’s clin-
ical condition improved significantly after the start of IVIG treat-
ment. Of the reviewed patients, 16 (55%) had received HSCTand
10 (34%) immunoglobulin replacement, some prior to HSCT.
Currently, choosing treatment for X-CID is difficult. Long-term
complications and prognosis of combined immunodeficiencies
remain unknown. In the future, X-CID patients should be recruited
to international registries and follow-up studies to collect informa-
tion in order to outline treatment options and protocols.
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